Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Moustafa Abdou: New Horizons in Hematology and Recent Drug Approvals
Moustafa Abdou/LinkedIn
Apr 4, 2026, 09:21

Moustafa Abdou: New Horizons in Hematology and Recent Drug Approvals

Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:

“New Horizons in Hematology: A Review of Recent Drug Approvals

Recent advances in hematology are rapidly transforming the management of both malignant and non-malignant blood disorders.

From gene therapy and non-factor treatments in hemophilia to targeted therapies such as JAK inhibitors and antibody–drug conjugates in hematologic malignancies, modern therapeutics are increasingly driven by precision medicine and molecular targeting.

Agents such as brentuximab vedotin have redefined lymphoma treatment, while ruxolitinib has significantly improved outcomes in myeloproliferative neoplasms.

In resistant leukemias, novel agents like omacetaxine offer alternative mechanisms to overcome treatment resistance.

Equally important are advances in supportive care.

G-CSF therapies, iron chelation, direct oral anticoagulants, and enzyme replacement therapies have reduced complications and improved quality of life across a wide range of hematologic conditions.

These developments highlight a comprehensive shift toward more effective, personalised, and safer treatment strategies in hematology.”

Stay updated with Hemostasis Today.

 

bleeding disorders Brentuximab vedotin DOACs G-CSF Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Iron chelation JAK Inhibitors Medicine Omacetaxine
NewsFeed